Amarantus BioScience Holdings, Inc. “Preparing Amarantus for the Up-list in 2H-14: Capital Markets Strategy”


Follow this company

Companies Mentioned

OTC:BB:AMBS
08/11/2014 [ACCESSWIRE]

New York, NY / ACCESSWIRE / August 11, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman’s Blog, co-written by the Company’s CEO, Mr. Gerald Commissiong and Chief Financial Officer, Mr. Robert Farrell, JD. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In their new blog, President and CEO Gerald Commissiong and Chief Financial Officer Robert Farrell, JD, discuss Amarantus’ preliminary proxy statement that was filed with the United States Securities and Exchange Commission on August 8th, 2014. The blog also details several matters that will be presented to current shareholders for approval  at the Company’s first Annual Shareholders Meeting on September 22nd in San Francisco. Read the full blog post from Mr. Gerald Commissiong and Mr. Farrell on TheChairmansBlog.com (http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/preparing-amarantus-list-2h-14-capital-markets-strategy/

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit http://www.amarantus.com/, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. http://www.thechairmansblog.com/

COMMENTS

Leave a comment...
 * 

Your Name
 *